Drugs / INO-4202
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02464670 | May 2015 → May 2018 | Ebola hemorrhagic fever | Inovio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-4202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02464670 ↗ |
| Modality | Vaccine | “Two DNA vaccine candidates (INO-4201 and INO-4202) targeting the EBOV glycoprotein (GP) were evaluated for safety, tolerability, and immunogenicity in a phase 1 clinical trial.” PMID 30891607 ↗ Jul 2019 |
| Route | Intramuscular | “INO-4202 delivered IM followed by Electroporation” NCT02464670 ↗ |